Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novogen Limited NVGN

Healthcare Drug Manufacturers - Specialty & Generic
"Novogen Ltd is a pharmaceutical drug development based on a simple benzopyran chemical structure. It is an emerging oncology-focused biotechnology company that develops anti-cancer drugs."

Recent & Breaking News (NDAQ:NVGN)

Novogen to Present at SACHS Cancer Bio Partnering & Investment Forum

PR Newswire February 22, 2015

Novogen Investor Briefing Well Received

PR Newswire February 19, 2015

Novogen to present at BIO & CEO Investor Conference 9th & 10th February, 2015

PR Newswire February 3, 2015

Novogen Announces Important Discovery in Regenerative Medicine Program

PR Newswire January 15, 2015

Novogen to Conduct Shareholder/Investor Briefing in New York

PR Newswire January 7, 2015

Novogen Raises An Additional A$1.75m in Private Placement to US Institutions for Aggregate Private Placement of A$5.85m

PR Newswire December 19, 2014

Novogen Announces Breakthrough Discovery in the Treatment of Melanoma

PR Newswire December 16, 2014

Novogen Provides Update On Progress Of Cantrixil Into The Clinic

PR Newswire December 15, 2014

Graham Kelly PhD, CEO & Chairman attended the Rodman & Renshaw 16th Annual Global Investment Conference

GlobeNewswire September 29, 2014

ABC TV Interview Discusses the Potential of Trilexium(TM) to Treat Brain Cancer

PR Newswire September 29, 2014

Novogen Announces Presentation at Rodman & Renshaw 16th Annual Healthcare Conference

PR Newswire September 3, 2014

Novogen Announces Results of General Meeting of Shareholders

PR Newswire August 13, 2014

Novogen Receives Funding Support To Commence Studies In Muscular Dystrophy

PR Newswire August 12, 2014

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

Business Wire August 11, 2014

Novogen And CanTx Appoint Contract Manufacturers To Produce Clinical Batches Of Cantrixil(TM)

PR Newswire July 25, 2014

Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant Ovarian Cancer Stem Cells

PR Newswire June 17, 2014

Novogen Identifies Highly Active Drug Candidates Against Prostate Cancer

PR Newswire May 27, 2014

Children's Oncology Drug Alliance (CODA) Formed to Facilitate Development of Treatments for Childhood Cancers

PR Newswire May 4, 2014

Novogen and Genea Announce Partnership to Investigate Promising New Approach to Neurodegenerative Diseases

PR Newswire May 2, 2014

Novogen and CanTx Experimental Drug, Trx-1, Proves Effective in Vivo

PR Newswire March 18, 2014